The Asia Pacific PEGylated Proteins Market should witness market growth of 12.1% CAGR during the forecast period (2022-2028).
Hemophilia A or B congenital disorders in adults and adolescents can be treated with the recombinant factor VIIa, Sevenfact. As a result, it is projected that regulatory backing and several product approvals for biologics will accelerate the industry's expansion. The funding for research and development of therapeutic proteins has expanded due to the ongoing regulatory support shown by the approvals of biological products.
Major pharmaceutical companies are refocusing their research and development budgets on biologics in an effort to develop fresh and efficient methods, tools, or drug delivery formulations. PEGylated proteins, a type of therapeutic, offer novel benefits such as improved half-life and drug stability in circulation. PEGylated substances are also non-toxic, water-soluble or hydrophilic, non-antigenic, and non-immunogenic, and the US FDA has so generally acknowledgedthem as safe.
These characteristics allow PEGylated proteins to remain in the body for a relatively long period of time, which finally results in a reduction in the frequency of dose and an increase in patient adherence to the therapy. The effective use of PEG molecules in biopharmaceuticals and the benefits that come with it have intensified research efforts for PEGylation technology and are anticipated to boost the market during the projected period.
The trend of gastrointestinal disease in the Asia-Pacific area has seen noticeable changes since the turn of the millennium. Since the region is home to over half of the world's population, these changes have a big impact on the burden of disease worldwide. Asia has been reported to have the greatest incidence of gastric cancer (GCA), which is still a very serious cancer. However, time-trend studies have revealed a decline in the incidence of GCA in some Asian nations.
The China market dominated the Asia Pacific PEGylated Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $171.3 million by 2028. The Japan market is estimated to grow a CAGR of 11.4% during (2022-2028). Additionally, The India market would display a CAGR of 12.8% during (2022-2028).
Based on Product & Services, the market is segmented into Consumables and Services. Based on Type, the market is segmented into Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin and Others. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutes. Based on Application, the market is segmented into Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck Millipore (Merck KGaA), Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology Co. Ltd., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd., Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Inc.
Hemophilia A or B congenital disorders in adults and adolescents can be treated with the recombinant factor VIIa, Sevenfact. As a result, it is projected that regulatory backing and several product approvals for biologics will accelerate the industry's expansion. The funding for research and development of therapeutic proteins has expanded due to the ongoing regulatory support shown by the approvals of biological products.
Major pharmaceutical companies are refocusing their research and development budgets on biologics in an effort to develop fresh and efficient methods, tools, or drug delivery formulations. PEGylated proteins, a type of therapeutic, offer novel benefits such as improved half-life and drug stability in circulation. PEGylated substances are also non-toxic, water-soluble or hydrophilic, non-antigenic, and non-immunogenic, and the US FDA has so generally acknowledgedthem as safe.
These characteristics allow PEGylated proteins to remain in the body for a relatively long period of time, which finally results in a reduction in the frequency of dose and an increase in patient adherence to the therapy. The effective use of PEG molecules in biopharmaceuticals and the benefits that come with it have intensified research efforts for PEGylation technology and are anticipated to boost the market during the projected period.
The trend of gastrointestinal disease in the Asia-Pacific area has seen noticeable changes since the turn of the millennium. Since the region is home to over half of the world's population, these changes have a big impact on the burden of disease worldwide. Asia has been reported to have the greatest incidence of gastric cancer (GCA), which is still a very serious cancer. However, time-trend studies have revealed a decline in the incidence of GCA in some Asian nations.
The China market dominated the Asia Pacific PEGylated Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $171.3 million by 2028. The Japan market is estimated to grow a CAGR of 11.4% during (2022-2028). Additionally, The India market would display a CAGR of 12.8% during (2022-2028).
Based on Product & Services, the market is segmented into Consumables and Services. Based on Type, the market is segmented into Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin and Others. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutes. Based on Application, the market is segmented into Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck Millipore (Merck KGaA), Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology Co. Ltd., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd., Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Inc.
Scope of the Study
By Product & Services
- Consumables
- Services
By Type
- Colony-stimulating Factor
- Interferons
- Recombinant Factor VII
- Erythropoietin
- Others
By End-user
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
By Application
- Cancer
- Autoimmune Diseases
- Hepatitis
- Multiple Sclerosis
- Hemophilia
- Gastrointestinal Disorders
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Merck Millipore (Merck KGaA)
- Thermo Fisher Scientific, Inc.
- NOF Corporation
- JenKem Technology Co. Ltd.
- Creative PEGworks
- Celares GmbH
- Quanta BioDesign, Ltd.
- Biomatrik, Inc.
- Iris Biotech GmbH
- Laysan Bio, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific PEGylated Proteins Market by Product & Services
Chapter 5. Asia Pacific PEGylated Proteins Market by Type
Chapter 6. Asia Pacific PEGylated Proteins Market by End-user
Chapter 7. Asia Pacific PEGylated Proteins Market by Application
Chapter 8. Asia Pacific PEGylated Proteins Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Merck Millipore (Merck KGaA)
- Thermo Fisher Scientific, Inc.
- NOF Corporation
- JenKem Technology Co. Ltd.
- Creative PEGworks
- Celares GmbH
- Quanta BioDesign, Ltd.
- Biomatrik, Inc.
- Iris Biotech GmbH
- Laysan Bio, Inc.
Methodology
LOADING...
